

RESEARCH ARTICLE

ANALYTICAL CHEMISTRY

SIMULTANEOUS ESTIMATION OF AMBROXOL HYDROCHLORIDE AND LORATADINE IN TABLET DOSAGE FORM BY USING UV SPECTROPHOTOMETRIC METHOD

ILANGO VAN PONNILAVARASAN¹, CHEBROLU.SUNIL NARENDRA KUMAR*¹, AND P.ASHA¹

College Of Pharmacy, Kovai Medical Centre Research And Educational Trust, Coimbatore,641048, India.



CHEBROLU.SUNIL NARENDRA KUMAR

College Of Pharmacy, Kovai Medical Centre Research And Educational Trust, Coimbatore,641048, India.

*Corresponding author

ABSTRACT

A novel, simple, rapid, precise, accurate, cost effective and reproducible spectrophotometric method has been developed for simultaneous estimation of ambroxol hcl and loratadine in combined tablet dosage form. The method employs measurement of absorbance at two wavelengths, 308nm and 245nm, of ambroxol and loratadine respectively. Beer's law obeyed in the concentration range of 10-50µg/ml and 10-50µg/ml for ambroxol and loratadine respectively. The proposed method is recommended for routine analysis since it is rapid, simple, accurate, and also sensitive and specific. Results of percentage recovery studies confirmed the accuracy of the proposed method. The present uv spectroscopic method was validated following the ICH guidelines¹⁷⁻¹⁸.

KEY WORDS

Ambroxol , Loratadine, Simultaneous equation method, Uv spectroscopy.


INTRODUCTION

Ambroxol hydrochloride¹ is chemically, 1-((2-Amino-3,5-dibromophenyl)methyl)amino)cyclohexanol monohydrochloride which is a semi synthetic derivative of vasicine from the Indian shrub "Adhatoda vasica". It is an expectoration improver and a mucolytic agent used in the treatment of bronchial asthma and chronic bronchitis. Ambroxol hydrochloride has also been reported to have a cough suppressing effect and anti inflammatory action. Recently the inhibition of nitric oxide dependent activation of soluble guanylate cyclase was suggested one of the molecular mechanism of the therapeutic action of ambroxol hydrochloride, also used in pulmonary alveolar proteinosis in pulmonary distress and infant respiratory distress syndrome.


Loratadine¹³ is chemically 4-[8-chloro-5,6-dihydro-11Hbenzo [5,6] cyclohepta [1,2-b] pyridin-11-ylidene]-1-piperidinecarboxylic acid ethyl ester with a potent antihistaminic agent

used in the treatment of urticaria and allergic rhinitis. . Literature survey showed that very few analytical methods have been reported for the estimation of Loratadine and Ambroxol Hydrochloride individually and in combination with other drugs like uv-visible spectrophotometry¹², liquid chromatography with fluorescence¹¹, LC-MS/MS⁵, RP-LC¹³, capillary electrophoresis⁸, HPLC with potentiometric detection², etc. However, there is no uv method reported for the simultaneous estimation of these drugs in combined dosage forms. fixed dose combination containing ambroxol hydrochloride (60mg) and loratadine (5mg) is available in the tablet dosage form in the market.

The objective of present study was to develop simple, precise, accurate and validated, economic and analytical methods for estimation of Ambroxol Hcl and Loratadine in tablet dosage forms.



Structure of Ambroxol hydrochloride:



Structure of Loratadine:



MATERIALS AND METHODS

APPARATUS:

All absorbance measurements were made on shimadzu uv-visible double beam spectrophotometer model shimadzu pharmaspec uv-1700 was employed with spectral band width of 0.5nm and wavelength accuracy of ± 0.3 nm with automatic wavelength corrections with a pair of 1cm uv matched quartz cells.

MATERIALS

The pure drug samples of ambroxol hydrochloride and loratadine were obtained from franco Indian pharma, Mumbai, india. Methanol AR grade was used throughout the experimental work. Tablets were purchased from local market (Lorfast-am) tablets containing ambroxol hydrochloride 60mg and loratadine 5mg per tablet.

METHOD

PREPARATION OF STANDARD STOCK SOLUTIONS:

Standard stock Solutions of ambroxol hydrochloride and loratadine were prepared by dissolving 25mg of ambroxol and quantity of loratadine equivalent to ambroxol base 25mg separately in 10ml of methanol. It was then sonicated for 10minutes and the final volume of both the solutions were made up to 25ml with methanol to get stock solutions containing 1000 μ g/ml each of ambroxol and loratadine in two different 25ml volumetric flasks.

SELECTION OF WAVELENGTH

Ambroxol and loratadine solutions 10 μ g/ml solutions were prepared separately and λ max of both drugs was scanned individually in the range of 400-200nm to determine the wavelength of maximum absorption for both the drugs. for estimation two wavelengths were selected, 308nm for ambroxol and 245nm for loratadine in the respective solvent.

STUDY OF BEER LAMBERTS LAW

Ambroxol and loratadine showed linearity with absorbance in the range of 10-50 μ g/ml and 10-50 μ g/ml at their respective maxima. correlation coefficients of ambroxol and loratadine were found to be 0.9987 and 0.9991. For simultaneous estimation of ambroxol and loratadine, a series of standard solutions were prepared by diluting appropriate volume of standard stock solutions, like 10,20,30,40 and 50 μ g/ml. The solutions were scanned in the range of 200-400nm against methanol as blank. Absorbance and absorptivities of series of standard solutions were recorded at selected wavelengths (λ_1) and (λ_2).

ANALYSIS OF TABLET FORMULATION

Twenty tablets of each containing 60mg of ambroxol hydrochloride and 5mg of loratadine were weighed accurately and finely powdered. From each triturate of the 20 tablets an amount equivalent to 50mg was weighed and transfer to 50ml volumetric flask. Containing 25ml methanol shaken for 10min, then volume was made up to 50ml with methanol and filtered through whatman filter paper No41 in to another 50ml volumetric flask washed residue with double distilled water and added washings to filtrate, volume of filtrate was made to 50ml mark with double distilled water.


The final mixed sample solution were prepared, correspond to 80 μ g/ml of ambroxol hydrochloride and 20 μ g/ml of loratadine. The absorbance of resulting solutions were measured at 308nm and 245nm. The concentration of ambroxol and loratadine present in the sample solution was calculated directly from absorbance value at 245nm and 308nm from calibration curve prepared using standard drug solutions. The Results of analysis of the tablet formulation is presented in table no.1.



TABLE NO : 1
Results of analysis of tablet formulation

Analyte %RSD	label claim (mg/tab)	Estimated amount	%Label claim estimated * (Mean± S.D.)
AMB HCL	60	59.46	99.18±0.0326 0.6275
LOR	5	4.83	99.83 ±0.0175 0.2301

*average of five determinations, R.S.D. relative standard deviation



overlain spectrum of Ambroxl and Loratadine

SIMULTANEOUS EQUATION METHOD

Two wavelengths selected for the method are 308nm and 245nm that are absorption maxima of ambroxol and loratadine respectively in methanol. The absorbances were measured at

the selected wavelengths and absorptivities ($A_1\%, 1\text{cm}$) for both the drugs at both wavelengths were determined as mean of three independent determinations. Concentrations in the sample were obtained by using following equations

$$\text{At } \lambda_1 \quad A_1 = ax_1bcx + ay_1bcy(308\text{nm})$$

$$\text{At } \lambda_2 \quad A_2 = ax_2bcx + ay_2bcy(245\text{nm})$$

$$C_x = \frac{A_2ay_1 - A_1ay_2}{ax_2ay_1 - ax_1ay_2} \dots\dots\text{eq. (i)}$$

$$C_y = \frac{A_1ax_2 - A_2ax_1}{ax_2ay_1 - ax_1ay_2} \dots\dots\text{eq. (ii)}$$

Where A_1 and A_2 are absorbance of mixture at 308nm and 245nm respectively, ax_1 and ax_2 are absorptivities of ambroxol and loratadine at λ_1 and λ_2 respectively, cx and cy are concentrations of ambroxol and loratadine respectively. Figure 1 represents the overlain spectra of both the drugs in 1:1 ratio and the criteria for obtaininig maximum precision (i.e. absorbance ratio $(A_2/A_1)/ax_2/ax_1$ and ay_2/ay_1)

by this method were calculated and found to be outside the range of 0.1-2.0 which is satisfied for both the ambroxol and loratadine in ratios of 1:1 and 1:2.

RECOVERY STUDIES²²⁻²³:

The method was validated according to ICH Q2B guidelines for validation of analytical



procedures in order to determine the linearity, precision, and accuracy for the analyte. Recovery studies by spiking different concentrations of pure drug in the pre analysed tablet samples with in the analytical concentration range of the proposed method.

The added quantities of the individual drugs were estimated by above method. The results of recovery studies were found to be satisfactory and the results are presented in table no.2.

TABLE NO : 2
Determination of percentage recovery

Drug In Standard Mixture		% Recovery \pm S.D.* Solution (μ g/ml)	
AMB	LOR	AMB	LOR
10	10	99.37 \pm 0.43	99.04 \pm 1.20
20	20	100.93 \pm 0.90	99.66 \pm 0.63
30	30	100.25 \pm 0.78	99.87 \pm 1.38

S.D.* for standard deviation, the results of mean of three readings (n=3).

RESULTS AND DISCUSSION

PRECISION:

Assay of the method precision (inter day precision) was evaluated by carrying out 3independent assays of test samples of ambroxol and loratadine. The intermediate precision (inter day precision) of the method was also evaluated by using shimadzu uv-visible double beam spectrophotometer model [SHIMADZU PHARMASPEC UV-1700] was employed with spectral band width of 0.5nm and wavelength accuracy of \pm 0.3nm with automatic wavelength corrections with a pair of 1cm uv matched quartz cells.

ACCURACY:

Accuracy of the method was studied by recovery experiments. The recovery experiments were performed by adding known amounts to tablet. The recovery was performed at 100% level at 3 different standard concentrations.

The recovery samples were prepared in before mentioned procedure, three different concentrations of the samples were prepared for each recovery level. The solutions were

then analysed, and the results of recovery studies were found to be satisfactory and the results are presented in table no:2.

LINEARITY:

The linearity of the response of the drugs was verified at 0-100ug/ml concentrations, the calibration graphs were obtained by plotting the absorbance versus the concentration data and were treated by linear regression analysis(table no) The equation of the calibration curve for ambroxol and loratadine obtained $Y=0.008x+0.011$ and $Y=0.042x+0.016$, the calibration curve were found to be linear in the afore mentioned concentrations. The correlation co-efficients (r^2)for ambroxol and loratadine were determined by 0.997 and 0.9991. Table no:3.

LIMIT OF DETECTION(LOD) AND LIMIT OF QUANTIFICATION (LOQ):

The LOD and LOQ of the ambroxol and loratadine were determined by using standard deviation of the response and slope approach as defined in ICH guidelines. The LOD and LOQ was found to be as in table no:3



Table No: 3
Regression And Optical Characteristics Of Ambroxol And Loratadine

Parameters	Value For AMB	Value For LOR
Beers law limit ($\mu\text{g/ml}$)	10-50	10-50
Correlation coefficient (r)	0.9987	0.9991
Regression equation	0.997	0.998
Slope	0.008	0.042
Intercept	0.011	0.016
LOD	2.31 $\mu\text{g/ml}$	0.482 $\mu\text{g/ml}$
LOQ	7 $\mu\text{g/ml}$	1.463 $\mu\text{g/ml}$

DETERMINATION OF ACTIVE INGREDIENTS IN TABLETS

The validated method was applied to the determination of ambroxol and loratadine in tablets. The Tablets were assayed and the results shown in (table no:1) indicating that the amount of drug in tablet samples met with requirements(99-100%of the label claim)

CONCLUSION

The developed method was found to be simple, sensitive, accurate, precise, reproducible, and can be used for routine quality control analysis of ambroxol hydrochloride and loratadine in bulk and pharmaceutical formulations.

ACKNOWLEDGEMENT

The authors thank to M/s. Fracno Indian pharma, Mumbai for providing gift samples of loratadine and ambroxol Hydrochloride.

REFERENCES

1. Pai PNS *et al.* reported Spectrophotometric determination of ambroxol hydrochloride. *Ind J Pharm Sci*; 67(6): 741-742,(2006).
2. Grzegorz Bazylak *ET al*, have been reported Simultaneous high-throughput determination of clenbuterol, ambroxol and bromhexine in pharmaceutical formulations by HPLC with potentiometric detection.32: 887-903,(2003).
3. A.Sanyanarayana *et al.* reported Simultaneous determination of montelukast and loratadine by HPLC and derivative spectrophotometric methods. *Journal of pharmaceutical and Biomedical analysis* 31: 359-368, (2003).
4. Pendharkar NA *et al.* Simultaneous estimation of Azithromycin and Ambroxool Hydrochloride in combined tablet dosage form by multicomponent mode of analysis. *Asian J.Research Chem.* 3(2):296-298,(2010).
5. Silvia imre .B *ET a*have been reported high-performance liquid chromatography with mass spectrometry (lc/ms/ms) method for determination of loratadine and its active metabolite descarboethoxylopratadine in human plasma.44: 652-657,(2007).
6. PawelÇ K. Kunicki *ET al*, have been reported Determination of loratadine in human plasma by high-performance liquid chromatographic method with ultraviolet detection.755: 331-335,(2001).
7. Dantu Durga Rao *ET al*, : have been reported A validated stability-indicating UPLC method for desloratadine and its



- impurities in pharmaceutical dosage forms.51:736-742,(2010).
8. M. Elisa Capella-Peiro ET al, 2006: have been reported Optimization by factorial design of a capillary zone electrophoresis method for the simultaneous separation of antihistamines352:41-49,(2006).
 9. N Harikrishnan et al. Development and validation of UV spectrophotometric methods of Loratadine in bulk and pharmaceutical formulation. Asian J.Research Chem. 3(2): 302-304.(2010).
 10. Goyal anju et al. Spectrophotometric methods for simultaneous estimation of cetirizine hydrochloride and ambroxol hydrochloride in tablet formulations Journal of pharmaceutical research vol.7, No.4, 248-250,(2008).
 11. Abolhsassan Ahmadiani et al.Rapid determination of loratadine in small volume samples by high-performance liquid chromatography with fluorescence detection. journal of chromatography B, 809: 227-230, (2004).
 12. I.singhvi have reported visible Spectrophotometric methods for the estimation of loratadine from tablets Ind J Pharm Sci.; 34:291-293, (2003).
 13. M.M. Mabrouk et al.Simultaneous estimation of loratadine and pseudoephedrine sulfate in pharmaceutical formulation by RP-LC and derivative spectrophotometry. Journal of pharmaceutical and Biomedical analysis 33: 597-604, (2003).
 14. Nilgun Gunden Goger et al. Quantitative dermination of ambroxol in tablets by derivative Uv spectrophotometric method and HPLC. Journal of pharmaceutical and Biomedical analysis 31:867-872,(2003).
 15. Pawel K. Kunicki et al. Determination of loratadine in human plasma by HPLC method with Uv detection. Journal of chromatography B.755: 331-335, (2001).
 16. Dina T. EL-Sherbiny et al. Simultaneous determination of loratadine and desloratadine in pharmaceutical preparations using liquid chromatography with a micro emulsion as eluent. Journal of pharmaceutical and Biomedical analysis 43:1236-1242,(2007).
 17. C. Barabas et al. LC determination of loratadine and related impurities. Journal of pharmaceutical and Biomedical analysis 29: 35-41, (2002).
 18. Kattaboina Suman et al. Formulation and optimization of directly compressible Ambroxol HCL controlled release matrix tablets. Research J.Pharm. and Tech.3(1): 263-266, (2010).
 19. Tai-Jun Hang et al. simultaneous determination and pharmacokinetic study of Roxithromycin and ambroxol hydrochloride in human plasma by LC-MS/MS. Clinica Chimica Acta 382: 20-24, (2007).
 20. Laurian Vlase et al. Determination of Loratadine and its active metabolite in human plasma by high performance liqid chromatography with mass spectrometry detection. Journal of pharmaceutical and Biomedical analysis 44: 652-657, (2007).
 21. Satinder Ahuja,Ahuja consulting, Calabash, North Carolina "Handbook of modern pharmaceutical analysis", published by academic press, A Harcourt science and technology company, san Francisco, page No:417.
 22. International Conference on Harmonization (ICH), Q2B: Validation of Analytical Procedures: Methodology, U.S Food and Drug Administration, Federal Register, May 1997, Vol. 62, Page No: 27463.
 23. International Conference on Harmonization, "Q2A: Text on Validation of Analytical Procedures," *Federal Register* 60(40): 11260–11262, (1995).